1. ALLA AKTIER
  2. NYHETER
  3. BBS-BIOACTIVE BONE SUBSTITUTES

BBS-Bioactive Bone Substitutes

Nyheter BBS-Bioactive Bone Substitutes Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

BBS-Bioactive Bone Substitutes Plc Apply for Delisting from Nasdaq First North

MARKN.

BBS-Bioactive Bone Substitutes Plc | Company Release | March 05, 2025 at 14:30:00 EET

The Board of Directors of BBS-Bioactive Bone Substitutes Plc ("BBS" or the "Company") resolved at its meeting on February 12, 2025, to file for bankruptcy. Subsequently, the Oulu District Court declared the Company bankrupt on February 17, 2025, at 1:00 PM (Decision Number: 25/4037, Case K 25/3957).
 
In light of this development, the Company has applied to delist its shares from the Nasdaq First North Growth Market, following applicable regulations. Once the company receives confirmation from Nasdaq First North, it will announce the final trading date for BBS shares in a separate press release.

For more information, please contact:
Attorney Valtteri Vuorenmaa
valtteri.vuorenmaa@fennolaw.fi
+358 50 350 2123

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

Distribution
Nasdaq Helsinki
https://www.bbs-artebone.fi/

BBS in brief
BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

Attachments
BBS-Bioactive Bone Substitutes Plc Apply for Delisting from Nasdaq First North

Datum 2025-03-05, kl 13:30
Källa MFN
Bifogade filer
BBS-Bioactive Bone Substitutes Plc Apply for Delisting from Nasdaq First North